Bio AI Is Quietly Shifting From Prediction to Production
A lot of the noise around bio AI still sounds like the AlphaFold era, meaning the story is about predicting structures and celebrating accuracy curves. The more consequential move in the last couple of weeks is that models are being pointed at bottlenecks that live downstream of prediction, like whether you can manufacture a protein drug efficiently, or whether you can integrate multiple assays into one coherent view of cell state that holds up across labs. MIT just published a concrete example of this shift. They describe using a large language model to optimize genetic sequences for proteins produced in yeast, with the goal of making manufacturing more efficient. That is not a glamorous demo compared to a structure prediction benchmark, but it is closer to where real cost and timelines live. If you can reduce iteration cycles in expression and production, you are not only predicting biology, you are compressing the pipeline that turns an idea into a therapy. https://news.mit.edu/2026...